Prices delayed by at least 15 minutes | Print
Fusion Antibodies PLC (FAB)
ORD 4POpen
3.75p
Previous close
3.75p
Trade high
3.72p
Volume
220,253
Year high
50.00p
Year low
3.02p
Dividend yield
-
Market capitalisation
£3.34 mn
P/E ratio
-
ISIN
GB00BDQZGK16
This share can be held in a Dealing accountISALifetime ISAJISASIPPand can be used with Dividend reinvestment
Share price
Company profile
Fusion Antibodies PLC offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly inthe areas of cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.
News
Recent trades
Date | Time | Price | Quantity | Value (£) |
---|---|---|---|---|
25/04/2024 | 04:10:19 | 3.501 | 75,000 | 2,625.75 |
25/04/2024 | 04:00:34 | 3.6023 | 75,000 | 2,701.73 |
25/04/2024 | 01:18:36 | 3.7142 | 68,952 | 2,561.02 |
25/04/2024 | 12:51:39 | 3.72 | 1,250 | 46.50 |
25/04/2024 | 08:05:03 | 3.7 | 51 | 1.89 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.